|
|
Article: Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer.
- Article from:
- PR Newswire
- Article date:
- August 8, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (BULLETIN BOARD: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against human pancreatic cancers in a mouse model.
Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against several types of human cancers in the test tube and against brain cancers in animal models. We have now found that two different ...